Modern possibilities of outpatient selection of antiarrhythmic therapy for frequent ventricular extrasystoles and paroxysmal ventricular tachycardia

Bereza N.V.

Main
Publications
Modern possibilities of outpatient selection of antiarrhythmic therapy for frequent ventricular extrasystoles and paroxysmal ventricular tachycardia

November 3, 2025

315

Therapy, General practice

Cardiology, Rheumatology

Bereza N.V.

УДК: 616.12-008.318

DOI: 10.32471/umj.1680-3051.270183

Keywords :

ambulatory 24-hour ECG monitoring,

ranolazine,

treatment,

ventricular extrasystole,

ventricular tachycardia

Specialities :

Therapy, General practice

Cardiology, Rheumatology

Resume

The article presents the results of practical experience in using ranolazine as an antiarrhythmic drug of the Id class, which has the ability to inhibit late sodium influx and suppress both early and late afterdepolarization. The use of ranolazine in the complex therapy of chronic coronary syndrome contributed to a significant reduction in the frequency of ventricular extrasystoles and ventricular tachycardia. According to the latest guidelines of the European Society of Cardiology (ESC) on the management of patients with chronic coronary syndrome 2024, ranolazine is considered an antianginal drug of choice with a class of evidence II A, which can be additionally prescribed in case of ineffectiveness of standard treatment at any step of the therapy of chronic coronary syndrome. At the same time, at the congress of arrhythmologists of the European Heart Rhythm Assotiation (EHRA) 2025, an updated classification of antiarrhythmic drugs was presented, in which ranolazine is assigned a separate subclass. The combination of antianginal and antiarrhythmic properties of ranolazine demonstrated its high efficacy in reducing ventricular arrhythmia and paroxysms of ventricular tachycardia in a patient for whom amiodarone was contraindicated. The clinical experience obtained may be useful for cardiologists, internists and general practitioners, since ranolazine has a small number of side effects, which allows it to be widely used in outpatient practice.

References

1. АHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrythmias and the Prevention of Sudden Cardiac Death (2018) JACC, 72(14): e91–e220. doi.org/10.1016/j.jacc.2017.10.054.
2. Zeppenfeld K., Tfelt-Hansen J., de Riva M. et al. (2022) 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J., 43(40): 3997–4126. doi: 10.1093/eurheartj/ehac262.
3. Коваленко В.М. та ін. (ред.) (2024) Серцево-судинні захворювання. Класифікація, стандарти діагностики та лікування. 7-ме вид., переробл. і доповн. Київ, Четверта хвиля, с. 68–70, 228–240.
4. McDonagh T.A., Metra M., Adamo M. et al. (2021) Task Forse for the diagnosis and treatment of acute and chronic heart failure of ESC, with the special contribution of the Heart Failure Assotiation (HFA) of the ESC. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J., 42(36): 3599–3726. doi: 10.1093/eurheartj/ehub368f.
5. McDonagh T.A., Metra M., Adamo M. et al. (2023) Focused Update of the diagnosis and treatment of acute and chronic heart failure: Developed by the risk forse for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur. Heart J., 44(37): 3627–3720. doi 10.1093/eurheartj/ehad195.
6. Eikelboom J.W., Connolly S.J., Bosch J. et al. (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. New Engl. J. Med., 377(14): 1319–1330.
7. Koren M.J., Crager M.R., Sweeney M. (2007) Long-Term Safety of a Novel Antianginal Agent in Patients With Severe Chronic Stable Angina The Ranolazine Open Label Experience (ROLE). J. Am. Coll. Cardiol., 49: 1027–1034.
8. Morrow D.A., Scirica B.M., Karwatowska-Prokopczuk E. et al. (2007) Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–STElevation Acute Coronary Syndromes The MERLIN-TIMI 36 Randomized Trial. JAMA, 297: 1775–1783.
9. Stone P.H., Gratsiansky N.A., Blokhin A. et al. (2006) Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. J. Am. Coll. Cardiol., 48: 566–575.
10. Chaitman B.R., Pepine C.J., Parker J.O. et al. (2004) Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA, 291(3): 309–316.
11. Kosiborod M., Arnold S.V., Spertus J.A. et al. (2013) Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina. J. Am. Coll. Cardiol., 61: 2038–2045.
12. Chaitman B.R., Skettino S.L., Parker J.O. et al. (2004) Anti-Ischemic Effects and Long-Term Survival During Ranolazine Monotherapy in Patients With Chronic Severe Angina. J. Am. Coll. Cardiol., 43: 1375–1382.
13. Інструкція для медичного застосування лікарського засобу Ранекса® 500/Ранекса® 1000.
14. Lei M., Wu L., Terrar D.A., Huang C.L.-H. (2018) Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation, 138(17): 1879–1896. doi: 10.1161/circulationaha.118.035455.
15. Lei M., Wu L., Terrar D.A., Huang C.L.(2025) The modernized classification of cardiac anti-arrhythmic drugs: its application to clinical practice. Heart Rhythm. doi: 10.1016/j.hrthm.2025.03.1997.
16. Merino J.L., Tamargo J., Blomstrm-Lundqvist C. et al. (2025) Practical Compendium of Antiarrhythmic Drugs: A Clinical Consensus Statement of the Europian Heart Rhythm Assotiation of the ESC Europace. doi.org/10.1093/europace/euaf076.
17. Antzelevitch C., Belardinelli L., Zygmunt A.C. et al. (2004) Electrophysiological effects of ranolasine, a novel antianginal agent with antiarrhythmic properties. Circulation, 110(8): 904–910.
18. Murray G.L. (2016) Ranolazine is an Effective and safe treatment of Adults with Symptomatic Premature Ventricular Contractions due to Triggered Ectopy. Int. J. Angiol., 25(4): 247–251. doi.org/10.1055/s-0036-1584880.
19. Vrints C., Andreotti F., Koskinas K. et al. (2024) 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur. Heart J., 45(36): 3415–3537.